Some lots of irbesartan being recalled due to contamination with suspected carcinogen
THURSDAY, Nov. 1, 2018 (HealthDay News) — Another hypertension drug is being recalled due to contamination that could pose a cancer risk, the U.S. Food and Drug Administration says.
Certain lots of irbesartan are being recalled by SciGen because they contain an industrial chemical that is a suspected carcinogen, CNN reported. The recalled drugs have “Westminster Pharmaceuticals” and “GSMS Inc.” on the label.
Another heart drug, valsartan, was recalled recently due to contamination with possible cancer-causing chemicals, CNN reported.
Not all medicines that contain valsartan or irbesartan are being recalled. The new recall covers only about 1 percent of irbesartan drug products available in the United States, according to the FDA.
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria